Pharmaceutical Technology4 天
NLX-101 by Neurolixis for Fragile X Syndrome: Likelihood of Approval
NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...
Pharmaceutical Technology4 天
Mavoglurant by Stalicla for Alcohol Dependence: Likelihood of Approval
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...